Kazia Therapeutics Files March 2025 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, disclosure
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed its March 6-K, standard disclosure for foreign issuers.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on March 31, 2025, reporting for the month of March 2025. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations company. This filing is made under the Securities Exchange Act of 1934 and indicates the company files annual reports under Form 20-F.
Why It Matters
This filing provides routine disclosure for Kazia Therapeutics, updating the SEC on its activities as a foreign private issuer. Investors can review this for any material updates not covered by their regular filings.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial results or significant corporate events.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000 (location) — Principal executive office address
- 20250331 (date) — Filing date and period of report
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of March 2025.
What is Kazia Therapeutics Limited's former company name?
Kazia Therapeutics Limited's former company name was Novogen Ltd, with a date of name change on 19981228.
Where is Kazia Therapeutics Limited's principal executive office located?
The company's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics file annual reports under Form 20-F or 40-F?
Kazia Therapeutics indicates it files annual reports under cover of Form 20-F.
What is the SIC code for Kazia Therapeutics?
The Standard Industrial Classification (SIC) code for Kazia Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).